Luseogliflozin Market Evenly Poised To Reach A Market Value of US$ By Share, Size and Leading Players (Novartis, Taisho Toyama, Mitsubishi Tanabe Pharma, CR Double-Crane) | Forecast to 2025

The demand for Luseogliflozin Market 2020 is anticipated to be high for the next few years. By considering this demand we provide latest Luseogliflozin Market Report which gives complete industry analysis, market outlook, size, growth and forecast till 2025. This report will assist in analyzing the current and future business trends, sales and revenue forecasts.

Overview of Global Luseogliflozin Market:

The Global Luseogliflozin Market research report is the study prepared by analysts, which contain a detailed analysis of drivers, restraints, and opportunities along with their impact on the Luseogliflozin Market growth (2020 - 2025).

As per the market research study, Luseogliflozin is a pharmaceutical drug used for the treatment of type 2 diabetes mellitus. In addition, Luseogliflozin exhibited increased urinary glucose excretion, with improved glucose tolerance and a significant reduction in fasting plasma glucose and postprandial plasma glucose, with body weight loss after chronic treatment in different animal models of diabetes and without an increase in plasma insulin. Clinical data in Japanese patients demonstrated that luseogliflozin was orally bioavailable, with a prolonged half-life, suitability for once-daily dosing and effective in significantly reducing glycated hemoglobin and fasting plasma glucose, with body weight loss.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/267973 .

The Global Luseogliflozin Market is segmented on the basis of Type, Application and Region. Based on the Type, the Global Luseogliflozin Market is sub-segmented into 2.5mg, 5mg and others. On the basis of Application, the Global Luseogliflozin Market is classified into Diabetes, Heart Disease, Periodontitis and others.

In terms of the geographic analysis, The Luseogliflozin Market in North America is expected to grow at the highest CAGR during the forecast period. Moreover, the presence of major players in the Luseogliflozin Market ecosystem results in the increasing adoption of these systems in North America.

Global Luseogliflozin Market Objectives:

1 To provide detailed information regarding key factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the Luseogliflozin Market

2 To analyze and forecast the size of the Luseogliflozin Market, in terms of value and volume

3 To analyze opportunities in the Luseogliflozin Market for stakeholders and provide a competitive landscape of the market

4 To define, segment, and estimate the Luseogliflozin Market based on deposit type and end-use industry

5 To strategically profile key players and comprehensively analyze their market shares and core competencies

6 To strategically analyze micromarkets with respect to individual growth trends, prospects, and contribution to the total market

7 To forecast the size of market segments, in terms of value, with respect to main regions, namely, Asia Pacific, North America, Europe, the Middle East & Africa, and South America

8 To track and analyze competitive developments, such as new product developments, acquisitions, expansions, partnerships, and collaborations in the Luseogliflozin Market

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Luseogliflozin Market Report 2020” @ https://www.businessindustryreports.com/buy-now/267973/single .

Top Leading Key Manufacturers are: Taisho Toyama, Novartis, Mitsubishi Tanabe Pharma, CR Double-Crane and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.

Top Medical Industry News:

Novartis (December 16, 2020) - Novartis announces positive FDA Advisory Committee recommendation for use of Entresto to treat patients with HFpEF - Novartis today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 that the data presented support the use of Entresto (sacubitril/valsartan) in treatment of patients with heart failure with preserved ejection fraction (HFpEF). This was based on data supporting the benefit of Entresto in reducing worsening heart failure (total heart failure [HF] hospitalizations and urgent HF visits) in patients studied in PARAGON-HF. If approved by the FDA, Entresto could become the first therapy indicated for use in treatment of patients with HFpEF, as well as the first medication approved for both major types of chronic heart failure, HFpEF and heart failure with reduced ejection fraction (HFrEF), both based on trials that included active comparators (valsartan and enalapril, respectively).

With no approved therapies for HFpEF to address the prevention of HF hospitalizations and urgent visits, a significant unmet medical need exists for a treatment to reduce the burden associated with this debilitating condition. The FDA is expected to make a decision on the supplemental New Drug Application (sNDA) in the first quarter of 2021.

“Managing HFpEF has historically been a clinical and scientific challenge due to the heterogeneity of the condition,” said Scott Solomon, MD, Professor of Medicine at Harvard Medical School and Brigham and Women's Hospital, and PARAGON-HF Executive Committee Co-Chair. “Today’s vote represents much needed progress in this area of unmet need and is a positive step toward bringing a potential therapy to millions of patients suffering from this type of heart failure.”

The Committee’s positive decision is based on the totality of evidence from efficacy and safety analyses, including findings presented from a pre-specified subgroup analysis of PARAGON-HF, the largest and only Phase III active-controlled study to date in patients with HFpEF and additional evidence from PARAMOUNT (a Phase II trial in HFpEF), as well as PARADIGM-HF (a Phase III trial in HFrEF). Data from PARAGON-HF demonstrated a favorable safety profile for Entresto in patients with HFpEF, which is in line with the vast clinical and post-marketing experience in HFrEF, and showed clinical benefit of Entresto in HFpEF patients.

“Our commitment to reimagine medicine through our extensive clinical trials program on heart failure has been unwavering, and we are encouraged by the Committee’s response today,” said David Soergel, MD, Global Head of Cardiovascular, Renal and Metabolic Drug Development, Novartis. “We appreciate the valuable insights shared by the patient and advocacy community about this devastating disease, and we look forward to FDA’s decision on the potential approval of this new indication.”

Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Luseogliflozin in these regions, from 2013 to 2025 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/267973 .

Major Points in Table of Contents:

Global Luseogliflozin Market Report 2020

1 Luseogliflozin Product Definition

2 Global Luseogliflozin Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Luseogliflozin Shipments

2.2 Global Manufacturer Luseogliflozin Business Revenue

2.3 Global Luseogliflozin Market Overview

2.4 COVID-19 Impact on Luseogliflozin Industry

3 Manufacturer Luseogliflozin Business Introduction

3.1 Taisho Toyama Luseogliflozin Business Introduction

3.2 Novartis Luseogliflozin Business Introduction

3.3 Mitsubishi Tanabe Pharma Luseogliflozin Business Introduction

3.4 CR Double-Crane Luseogliflozin Business Introduction

………………. Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.